RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Tubeimuside I 提高基于具核梭杆菌树突状细胞的治疗性疫苗对抗结直肠癌的疗效
英文原题：Tubeimuside I improves the efficacy of a therapeutic Fusobacterium nucleatum dendritic cell-based vaccine against colorectal cancer.
查看英文原题
Tubeimuside I improves the efficacy of a therapeutic Fusobacterium nucleatum dendritic cell-based vaccine against colorectal cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
在本研究中，我们提供了一种开发针对 CRC 的 DC 疫苗的有效策略，并强调了进一步理解由 F.
研究思路结论见上方概要
背景
具核梭杆菌（F. nucleatum）感染已被证实与结直肠癌（CRC）的发生、化疗耐药及免疫逃逸相关。该微生物、宿主细胞与免疫系统在CRC进展全过程中的复杂关系，使得新的治疗方法的开发变得困难。
方法
我们开发了一种新的树突状细胞（DC）疫苗，以探究CRC免疫治疗策略的抗肿瘤疗效。通过介导细菌、肿瘤和宿主之间特定模式的相互作用，我们发现了一种新的植物来源佐剂——管花肉苁蓉苷I（TBI），它同时提高了DC疫苗的疗效并抑制了F. nucleatum感染。将TBI包封在纳米乳剂中极大地提高了药物疗效，并减少了药物剂量和给药次数。
结果
纳米乳包裹的TBI DC疫苗表现出优异的抗菌和抗肿瘤效果，并通过抑制肿瘤的发展和进展提高了CRC小鼠的生存率。
展开英文摘要原文
METHODS
We developed a new dendritic cell (DC) vaccine to investigate the antitumor efficacy of CRC immunotherapy strategies. By mediating a specific mode of interaction between the bacteria, tumor, and host, we found a new plant-derived adjuvant, tubeimuside I (TBI), which simultaneously improved the DC vaccine efficacy and inhibited the F . nucleatum infection. Encapsulating TBI in a nanoemulsion greatly improved the drug efficacy and reduced the drug dosage and administration times.
RESULTS
The nanoemulsion encapsulated TBI DC vaccine exhibited an excellent antibacterial and antitumor effect and improved the survival rate of CRC mice by inhibiting tumor development and progression. DISCUSSION: In this study, we provide a effective strategy for developing a DC-based vaccine against CRC and underlies the importance of further understanding the mechanism of CRC processes caused by F. nucleatum .
论文信息
- 作者
- Tong Y、Lu G、Wang Z、Hao S、Zhang G、Sun H
- 第一作者单位
- Department of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, China.China
- 通讯作者单位
- Department of Microbiology and Biochemical Pharmacy, National Engineering Research Center of Immunological Products, College of Pharmacy, Third Military Medical University, Chongqing, China.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Frontiers in immunology2023
- 原文标识
- PubMed 37207216 · DOI 10.3389/fimmu.2023.1154818
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →